Hypoalbuminemia Clinical Trial
Official title:
The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood
To test whether intravenous albumin can decrease the rebleeding rate or shorten the duration of hospitalization in patients with peptic ulcer bleeding and hypoalbuminemia.
Peptic ulcer bleeding is a common but potentially lethal disease. Recurrent bleeding is an
independent risk factor for mortality. Inhibition of gastric acid secretion by intravenous
proton pump inhibitor infusion can have a positive impact on the prevention of ulcer
rebleeding after successful endoscopic therapy. However, the rebleeding rate can still be
high in patients with comorbid illnesses even after proton pump inhibitor usage.
Hypoalbuminemia has been reported to be a significant predictor of poor prognosis in patients
with comorbid illnesses. Low serum albumin levels are associated with poor prognosis of wound
healing and peptic ulcer bleeding; therefore, it is worthy to conduct a head-to-head
comparison to validate whether administration of albumin can be helpful in improving the
control of bleeding peptic ulcers, especially in patients with comorbid illnesses.
The albumin level may reflect upstream pathologic processes, such as stress or
co-morbidities. Albumin administration may interrupt the downstream chain of poor outcome and
thus maintain a favorable homeostasis in critically ill patients, and reduce morbidity.
However, the clinical benefit of controlling peptic ulcer bleeding with exogenous albumin
remains uncertain, and thus administration of albumin is not widely applied. Accordingly, the
investigators conducted this pilot intervention to test whether short-term exogenous albumin
administration can improve the control of peptic ulcer bleeding in hypoalbuminemic patients,
who are at high risk of recurrent bleeding.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05050851 -
Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
|
||
| Terminated |
NCT00529633 -
The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
|
Phase 3 | |
| Active, not recruiting |
NCT03675906 -
The Relationship Between Hypoalbuminemia and Development of Acute Kidney Failure (AKI) According to KDIGO Criteria
|
||
| Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
| Completed |
NCT03569410 -
The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients
|
N/A | |
| Terminated |
NCT02457702 -
Mitochondrial Function in Patients With Severe Liver Disease
|
N/A | |
| Active, not recruiting |
NCT02288494 -
Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach
|
N/A | |
| Completed |
NCT02765061 -
Hyponatremia and Hypoalbuminemia is Morbimortality Predictors in Coronary Artery Bypass Graft Surgery
|
N/A | |
| Completed |
NCT03167645 -
SUbstition of PERioperative Albumin Deficiency Disorders
|
Phase 4 | |
| Recruiting |
NCT05797649 -
Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis
|
||
| Completed |
NCT01542749 -
Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer
|
N/A | |
| Completed |
NCT00723762 -
Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients
|
N/A | |
| Completed |
NCT00561093 -
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
|
Phase 3 | |
| Completed |
NCT04046263 -
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
|
Phase 4 | |
| Completed |
NCT00597025 -
Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin
|
N/A | |
| Completed |
NCT06355479 -
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
|
Phase 3 |